http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Wattanaamornkiet, Wanpen (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis
Cegielski, J. Peter,Dalton, Tracy,Yagui, Martin,Wattanaamornkiet, Wanpen,Volchenkov, Grigory V.,Via, Laura E.,Van Der Walt, Martie,Tupasi, Thelma,Smith, Sarah E.,Odendaal, Ronel,Leimane, Vaira,Kvasnov Oxford University Press 2014 Clinical Infectious Diseases Vol.59 No.8
<P>Nearly 15% of multidrug-resistant (MDR) tuberculosis cases developed resistance to the fluoroquinolones, the second-line injectable drugs, or both during treatment for MDR tuberculosis. The rate of acquired resistance was significantly lower in programs that met specific performance criteria.</P><P><B><I>Background.</I></B> Increasing access to drugs for the treatment of multidrug-resistant (MDR) tuberculosis is crucial but could lead to increasing resistance to these same drugs. In 2000, the international Green Light Committee (GLC) initiative began to increase access while attempting to prevent acquired resistance.</P><P><B><I>Methods.</I></B> To assess the GLC's impact, we followed adults with pulmonary MDR tuberculosis from the start to the end of treatment with monthly sputum cultures, drug susceptibility testing, and genotyping. We compared the frequency and predictors of acquired resistance to second-line drugs (SLDs) in 9 countries that volunteered to participate, 5 countries that met GLC criteria, and 4 countries that did not apply to the GLC.</P><P><B><I>Results.</I></B> In total, 832 subjects were enrolled. Of those without baseline resistance to specific SLDs, 68 (8.9%) acquired extensively drug-resistant (XDR) tuberculosis, 79 (11.2%) acquired fluoroquinolone (FQ) resistance, and 56 (7.8%) acquired resistance to second-line injectable drugs (SLIs). The relative risk (95% confidence interval [CI]) of acquired resistance was lower at GLC-approved sites: 0.27 (.16–.47) for XDR tuberculosis, 0.28 (.17–.45) for FQ, and 0.15 (.06–.39) to 0.60 (.34–1.05) for 3 different SLIs. The risk increased as the number of potentially effective drugs decreased. Controlling for baseline drug resistance and differences between sites, the odds ratios (95% CIs) were 0.21 (.07–.62) for acquired XDR tuberculosis and 0.23 (.09–.59) for acquired FQ resistance.</P><P><B><I>Conclusions.</I></B> Treatment of MDR tuberculosis involves substantial risk of acquired resistance to SLDs, increasing as baseline drug resistance increases. The risk was significantly lower in programs documented by the GLC to meet specific standards.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
